Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleoporin NDC1 (NDC1) is an evolutionarily conserved, integral membrane nucleoporin and a core structural component of the nuclear pore complex (NPC), where it regulates the assembly, insertion, and stability of the NPC in the nuclear envelope[1][5]. NDC1 anchors the soluble nucleoporin ALADIN and functions as a critical bridge, facilitating selective protein import into the nucleus and maintaining nuclear-cytoplasmic compartmentalization[1][3]. Its topology features six transmembrane segments and multiple cytoplasm- and nucleoplasm-exposed domains, consistent with its role as a scaffold for complex assembly and membrane integration[2]. Loss or mutation of NDC1 disrupts normal NPC function, causes mislocalization of NPC constituents, and is linked to disorders such as triple A syndrome-like diseases and neuropathy[1][2][3]. In cancer, notably hepatocellular carcinoma, aberrant NDC1 overexpression can potentiate oncogenic pathways promoting cell proliferation and invasion[1]. NDC1 is also crucial in male gametogenesis through interactions with septin proteins that are vital for correct nuclear membrane morphology during sperm development[1]. No approved therapies or drugs target NDC1 directly, and it is not classified as a typical small molecule drug target (such as a receptor or enzyme)[1][5]. Summary: Nucleoporin NDC1 (NDC1, also known as TMEM48) is an evolutionarily conserved, integral transmembrane nucleoporin that is vital for nuclear pore complex assembly, nuclear envelope integrity, and nucleocytoplasmic transport; although highly relevant to disease and cellular biology, it is not currently considered a direct therapeutic target nor a receptor/enzyme[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleoporin NDC1 (NDC1).